@article{JGO29063,
author = {Gerald Li and Dean Pavlick and Jon H. Chung and Todd Bauer and Bradford A. Tan and Julio Peguero and Patrick Ward and Andre Kallab and Jose Bufill and Anthony Hoffman and Ahad Sadiq and Jeff Edenfield and Jie He and Matthew Cooke and Jason Hughes and Brady Forcier and Michelle Nahas and Phil Stephens and Siraj M. Ali and Alexa B. Schrock and Jeffrey S. Ross and Vincent A. Miller and Jeffrey P. Gregg},
title = {Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy},
journal = {Journal of Gastrointestinal Oncology},
volume = {10},
number = {5},
year = {2019},
keywords = {},
abstract = {Background: Liquid biopsy offers the ability to non-invasively analyze the genome of a tumor through circulating tumor DNA (ctDNA) to identify targetable and prognostic genomic alterations. Few studies have rigorously analyzed ctDNA results and determined the fidelity with which they recapitulate the genomics of a sequenced tissue sample obtained from the same tumor. The clinical utility study (CUS) for the FoundationACT™ ctDNA assay (Foundation Medicine, Cambridge, MA, USA; NCT02620527) is a multi-center prospective clinical study for multiple solid tumor types to compare genomic profiling of paired tissue and blood samples from the same patient. In this subset of the study, paired specimens from 96 patients with colorectal cancer (CRC) were analyzed with comprehensive genomic profiling (CGP) of the tumor tissue sample (FoundationOne®) and blood sample (FoundationACT™).
Methods: Both samples underwent CGP using the hybrid capture-based Illumina Hi-Seq technology. Maximum somatic allele frequency (MSAF) was used to estimate the fraction of ctDNA in the sample. The set of genes and targeted regions common to both tumor and liquid were compared for each subject.
Results: Among these patients, 61% were male; 74% had clinical stage IV disease, 19% had clinical stage III disease, and 7% had clinical stage II disease. Time between the tissue biopsy and liquid biopsy (range, 0–709 days) had a significant impact on the positive percent agreement (PPA) between the two assays. Eighty percent of cases had evidence of ctDNA in the blood (MSAF >0). For all cases with MSAF >0, 171 base substitutions and insertions/deletions (indels) were identified in the tumor, and 79% (PPA) of these identical alterations were also identified in matched ctDNA samples; PPA increased to 87% for cases },
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/29063}
}